Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

6  Enrolling
7  Total Trials
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LU...
Enrolling
Conditions: Ulcerative Colitis
Trial Name
LUCENT 3
Drugs: Mirikizumab
Age
18 - 80 years
Phase
III
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-URGE)
Enrolling
Conditions: Ulcerative Colitis
Trial Name
LUCENT-URGE
Drugs: Mirikizumab
Age
≥18 years
Phase
III
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis (SHINE-2)
Enrolling
Conditions: Ulcerative Colitis
Trial Name
SHINE-2
Drugs: LY3074828
Age
2 - 17 years
Phase
III
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)
Enrolling
Conditions: Crohn's Disease
Trial Name
VIVID-2
Drugs: Mirikizumab
Age
≥18 years
Phase
III
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-O...
Enrolling
Conditions: Crohn's Disease
Trial Name
SHINE-ON
Drugs: Mirikizumab
Age
2 - 19 years
Phase
III
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY)
Enrolling
Conditions: Crohn's Disease
Trial Name
AMAY
Drugs: Mirikizumab
Age
2 - 17 years
Phase
III

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
1 
Completed Enrollment
7  Total Trials
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Completed Enrollment
Conditions: Ulcerative Colitis
Trial Name
LUCENT 2
Drugs: Mirikizumab, Placebo
Age
18 - 80 years
Phase
III